Form 4: BeOne Medicines COO Sells Shares for Tax Withholding Following RSU Vesting

BeOne Medicines Ltd.'s President and COO, Wu Xiaobin, sold a total of 2,173 American Depositary Shares across two days in June 2025 to cover tax obligations related to the vesting of restricted share units.

Summary

• Wu Xiaobin, President and COO of BeOne Medicines Ltd. (ONC), reported sales of American Depositary Shares (ADSs).
• On June 16, 2025, Mr. Wu sold 1,443 ADSs at a weighted average price of $265.4695, with prices ranging from $265.21 to $266.01.
• Also on June 16, 2025, an additional 100 ADSs were sold at $266.22.
• On June 17, 2025, Mr. Wu sold 630 ADSs at $250.8686.
• These sales, totaling 2,173 ADSs, were conducted to satisfy mandatory tax withholding provisions associated with the vesting of previously granted restricted share unit (RSU) awards.
• Following these transactions, Mr. Wu's direct beneficial ownership of American Depositary Shares is 0, while he continues to indirectly own 4,000 ADSs through his wife.
• Each American Depositary Share represents 13 Ordinary Shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The sales are for tax withholding purposes related to RSU vesting, which is a routine and expected event for executive compensation, not indicative of a negative outlook on the company.

Positives

• The sales were for tax withholding purposes, indicating the vesting of previously granted restricted share units, which is a positive for the executive as it represents a realization of compensation.

Negatives

• The sales resulted in a reduction of the President and COO's direct beneficial ownership of American Depositary Shares to zero.

Future Outlook

The document indicates that unvested restricted share units are subject to accelerated vesting upon certain termination events, and future vesting will occur on anniversaries of June 15, 2023, and June 16, 2021, subject to continued service.

Industry Context

This filing is a routine insider transaction report, common in the biotechnology or pharmaceutical industry for executives receiving equity compensation. It reflects standard practices for managing tax obligations upon the vesting of restricted stock units, which are a common form of executive incentive in growth-oriented sectors like pharmaceuticals.

Comparison to Industry Standards

• This Form 4 filing details a standard transaction for an executive covering tax obligations upon the vesting of restricted share units. Such sales are common across all industries, including pharmaceuticals, and do not reflect a specific performance comparison to industry peers.
• Companies like Pfizer (PFE), Johnson & Johnson (JNJ), or Merck (MRK) also see similar tax-related insider sales when their executives' equity awards vest, indicating this is a standard operational event rather than a unique financial performance indicator.

Related Party Transactions

• The reported transactions involve the sale of shares by a key executive (Wu Xiaobin) to cover tax obligations related to his compensation, which is a common type of related party transaction in the context of executive equity awards.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even for tax purposes, slightly reduces the executive's direct equity ownership, though indirect ownership remains.
• Employees: The vesting of RSUs and subsequent tax-related sales are standard components of executive compensation, which can be seen as a positive for executive retention and motivation.

Next Steps

• Continued vesting of restricted share units on anniversaries of June 15, 2023, and June 16, 2021, subject to continued service.

Key Dates

Recommendation

Keywords

BeOne Medicines Ltd., ONC, SEC Form 4, Insider Trading, Restricted Share Units, RSU Vesting, Tax Withholding, Executive Compensation, Wu Xiaobin, American Depositary Shares, ADS